Verrica Pharmaceuticals (VRCA) Doses First Patients in Phase 3 Common Warts Trial

Verrica Pharmaceuticals Inc. (VRCA) announced on June 22, 2026, it has dosed the first U.S. and Japanese patients in its Phase 3 COVE-3 trial for YCANTH (cantharidin) to treat common warts. This development marks a significant step in the company's efforts to expand the market potential for its lead product. YCANTH is currently FDA-approved for molluscum contagiosum. The COVE-3 trial aims to evaluate the drug's safety and efficacy for common warts, a condition affecting an estimated 22 million individuals in the U.S. alone. Successful trial results could substantially increase YCANTH's addressable market and future revenue for Verrica. The company anticipates reporting top-line data from the COVE-3 trial in late 2027.